

Dr Reddy's launches generic fracture drug

07 March 2013 | News | By BioSpectrum Bureau



Hyderabad: Dr Reddy's Laboratories (DRL) launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Novartis' Zometa (zoledronic acid) 4 mg/5 mL Injection in the US.

The product was launched following the approval by the US Food & Drug Administration (US FDA) of Dr Reddy's Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/5 mL).

Dr Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.